Is the Trend Turning for This Psychedelic Stock?
Source: Clive Maund for Streetwise Reports  (4/19/21)
Technical analyst Clive Maund charts Delic Inc. and explains why he considers the stock attractive at this point. More >

Ardelyx to Receive $5M Milestone Payment as Japan Partner Initiates Phase 3
Source: Streetwise Reports  (4/15/21)
Ardelyx Inc. shares traded 11% higher after Kyowa Kirin Co. Ltd., its collaborative partner in Japan, initiated four Phase 3 clinical trials of tenapanor for treatment of hyperphosphatemia. More >

Biotech Company Acquires Therapeutics Firm, Gains 'Gem' in the Portfolio
Source: Streetwise Reports  (4/14/21)
Dawson James Securities advised it is maintaining its "Buy" rating after Sorrento Therapeutics announced the acquisition of ACEA Therapeutics for $38 million in stock. More >

Novocure Shares Climb 50% on Acceleration of Phase 3 Lung Cancer Trial
Source: Streetwise Reports  (4/13/21)
Novocure Ltd. shares reached a new 52-week high after the company reported an update from its Phase 3 Pivotal LUNAR trial of tumor treating electrical fields in non-small cell lung cancer. More >

Affimed NV Shares Rise 20% on Initial Data from Phase 1 R/R CD30-Positive Lymphoma Trial
Source: Streetwise Reports  (4/9/21)
Affimed NV shares reached a new 52-week high price after the company presented initial data from a Phase 1 trial of its AFM13 that shows potential to help NK cells target and destroy cancer cells. More >

Gene Therapy Restoring Light Sensitivity 'Showed Impressive Dose-Response Improvements'
Source: Streetwise Reports  (4/7/21)
Roth Capital Partners advised that Applied Genetic Technologies co-development of BS01 with Bionic Sight "validates its gene therapy capabilities." More >

Biopharma's Phase 2b/3 Alzheimer's Disease Trial Approved to Continue
Source: Streetwise Reports  (4/7/21)
Anavex Life Sciences' study, its drug's mechanism of action and the company's upcoming catalysts are covered in a Dawson James Securities report. More >

Biohaven Expects Net Revenue of $43.8 Million in Q1 for Its Migraine Medicine
Source: Streetwise Reports  (4/7/21)
Biohaven Pharmaceutical shares traded 10% higher after the company reported that in Q1/21 net product revenue for its migraine drug NURTEC ODT is estimated to be approximately $43.8 million. More >

United Therapeutics Shares Rise 15% as FDA Clears Pathway to Launch Tyvaso to Treat PH-ILD
Source: Streetwise Reports  (4/1/21)
United Therapeutics shares reached a new 52-week high after the firm reported that the U.S. FDA granted approval to commercially launch its Tyvaso® Inhalation Solution to treat patients with pulmonary hypertension associated with interstitial lung disease. More >

Pharmaceutical Development Company Added to First Psychedelic Stock Index ETF
Source: Streetwise Reports  (3/30/21)
Being included in the Horizons Psychedelic Stock Index Exchange Traded Fund will afford Algernon Pharmaceuticals greater investor exposure. More >

Data from Humanigen's Phase 3 COVID-19 Trial Show 54% Increase in Survival Rates
Source: Streetwise Reports  (3/29/21)
Shares of Humanigen Inc. traded 67% higher after the company reported positive topline results from its Phase 3 lenzilumabâ„¢ study indicating significant improvement in survival of hospitalized COVID-19 pneumonia patients without the need for mechanical ventilation. More >

ProQR Shares Gain 62% on Stellar Results in Phase 1/2 Usher Syndrome Trial
Source: Streetwise Reports  (3/25/21)
ProQR Therapeutics shares reached a new 52-week high after the company reported highly positive results from its Phase 1/2 Stellar trial of QR-421a in adults with Usher syndrome and non-syndromic retinitis pigmentosa (nsRP) due to USH2A exon 13 mutations. More >

Biopharma to Request U.S. Emergency Use Authorization for COVID-19 Vaccine in April
Source: Streetwise Reports  (3/24/21)
Catalysts expected in 2021-2022 regarding Ocugen's pipeline therapeutics are discussed in a ROTH Capital Partners report. More >

Aptose Biosciences Shares Rise 55% on Q4 Financial Results and Promising Clinical Trials
Source: Streetwise Reports  (3/24/21)
Aptose Biosciences Inc. shares traded 55% higher after the company posted Q4 and FY/20 financial results and provided an update on the status of its drug candidates in ongoing clinical trials investigating treatments for life threatening hematologic cancers. More >

Mental Health Firm Partners with Merck on Treatment-Resistant Depression Trial
Source: Streetwise Reports  (3/22/21)
Novamind Inc. reported it is teaming up with Merck to conduct a new Phase 2a study addressing treatment-resistant depression at a key clinical research site owned by its subsidiary company Cedar Clinical Research. More >

The Covid-19 Issue Too Many Are Ready to Overlook, and the Investing Opportunity It Creates
Source: KSS, MD, PhD, for Streetwise Reports  (3/22/21)
Have we forgotten about good Covid 19 Therapeutics? KSS MD PhD, editor-in-chief of PubBio.co, discusses three gems investors should know about. More >

Clovis Oncology Shares Rise on Positive Data from Phase 3 Ovarian Cancer Trial
Source: Streetwise Reports  (3/19/21)
Shares of Clovis Oncology Inc. traded 55% higher after it reported that in the Phase 3 ARIEL4 study Rubraca (rucaparib) significantly improved progression-free survival versus chemotherapy in patients with later-line ovarian cancer associated with a BRCA Mutation. More >

Biopharma Advances Alcohol-Associated Hepatitis Trial, Receives Analgesia Drug Approval
Source: Streetwise Reports  (3/17/21)
These corporate events and the Q4/20 financials of DURECT are summarized in an H.C. Wainwright & Co. report. More >

Pharma Developer to Release Topline Data from Phase 2b COVID-19 Trial by Month-End
Source: Streetwise Reports  (3/16/21)
Algernon Pharmaceuticals reported that it expects to release topline results from the Phase 2b portion of its multinational Phase 2b/3 COVID-19 Ifenprodil study sometime during the last week of March 2021. More >

Oncternal Therapeutics Shares Trade Higher After Firm Reports 39% Growth in FY20 Grant Revenue
Source: Streetwise Reports  (3/12/21)
Oncternal Therapeutics shares traded 18% higher after the company reported Q4/20 and FY/20 financial results showing higher revenues from grants and improved operating expense without incurring any reductions in Research and Development activities. More >

Vir Shares Head Higher as Phase 3 COVID-19 Trial with GSK Achieves 85% Reduction in Hospitalization and Death
Source: Streetwise Reports  (3/11/21)
Vir Biotechnology shares traded 30% higher after the company together with its development partner GlaxoSmithKline reported that in the Phase 3 COMET-ICE trial VIR-7831 was shown to reduce hospitalization and risk of death in early treatment of adults with SARS-CoV-2. More >

Biopharma Begins Phase 2 COVID Clinical Trial
Source: Streetwise Reports  (3/10/21)
An update on two of Can-Fite BioPharma's studies involving its lead drug candidate Piclidenoson is provided in a Dawson James report. More >

Amgen Offers $1.9 Billion to Acquire Five Prime Therapeutics
Source: Streetwise Reports  (3/4/21)
Five Prime Therapeutics shares traded 78% higher after the company reported it entered into a definitive agreement to be acquired by biotech giant Amgen for $38 per share in cash. More >

U.S. Biopharma Making a 'Bold Move into a Large Market Opportunity'
Source: Streetwise Reports  (3/3/21)
This latest undertaking of Dicerna Pharmaceuticals and the near-term catalysts of some of its other programs are described in an H.C. Wainwright & Co. report. More >

Biopharma Chooses Firm to Co-Conduct Psychedelic Dose Trial
Source: Streetwise Reports  (3/2/21)
Algernon Pharmaceuticals aims to begin the study as soon as it receives the drug from the manufacturer. More >